shared mechanism with cutaneous symptoms. In the present study we evaluated 27 muscle afferent neuron function in this rat model of CIPN. The mechanical 28 threshold of muscle afferents in rats exposed to paclitaxel was not significantly 29 different from the mechanical threshold of muscle afferents in control animals 30 (P=0.07). However, paclitaxel did produce a marked increase in the number of 31 action potentials elicited by prolonged suprathreshold fixed intensity mechanical 32 stimulation, and also a marked increase in the conduction velocity. In addition, 33 the interspike interval (ISI) analysis (to evaluate the temporal characteristics of 34 the response of afferents to sustained mechanical stimulation), showed a 35 significant difference in rats treated with paclitaxel; there was a significantly 36 greater percentage ISI of paclitaxel-treated muscle afferents with 0.01 and 0.02 s 37 interspike interval. In contrast, an analysis of variability of neuronal firing over 38 time (CV2 analysis) showed no effect of paclitaxel administration. These effects 39 Bonferroni post hoc test, P<0.05, control vs. paclitaxel exposed, Fig. 3 ). Although 231 we found no difference in CV2 values for muscle afferents in paclitaxel-treated 232 compared to control rats (data not shown), in addition to substantial increase 233 response to sustained suprathreshold stimulation in muscle afferents from 234 paclitaxel treated rats, there was also a change in firing patterns in theses 235 afferents. 236
Conduction velocity 237
Taxol sensitizes muscle afferents
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In paclitaxel-treated rats, the conduction velocity of muscle 238 afferents (2.09 ± 0.17 m/sec, n = 31) was significantly faster than that of afferents 239 in control animals (1.25 ± 0.11 m/sec, n = 40, Student's t-test, with Welch's 240 correction, P<0.0001; D'Agostino and Pearson omnibus normality test for control 241 fibers, P=0.006 does not pass normality test; paclitaxel-treated fibers, passes 242 normality test) (Fig. 4) . The frequency distribution of conduction velocities in 243 fibers of paclitaxel-treated and control fibers indicates a shift in the distribution 244 of conduction velocity, with a higher percentage of faster-conducting fibers in 245 NLB rats (Fig. 5) . Thus, while not excluding a contribution of a difference in 246 percentage of type III and type IV fibers that were sampled in the paclitaxel 247 treated versus control groups of rats, the shift in distribution is most compatible 248 with the suggestion that our findings are explained by an increase in conduction 249 velocity induced by paclitaxel in muscle afferents. While it is possible that 250 paclitaxel treatment has a preferential effect on a subset of neurons, e.g. more 251
superficial neurons, leaving a greater proportion of deeper terminals that may 252 require more force to be activated, our methodology does not distinguish the 253 superficiality of a particular fiber's receptive field. However, given the relatively 254 large increase in conduction velocity (~67%), it is likely that at least some of the 255 observed difference is due to changes in conduction velocity in the axon. The finding that the conduction velocity in muscle afferents was increased 315 by paclitaxel was unexpected, not only because of our prior finding that 316 paclitaxel did not produce a change in conduction velocity in cutaneous afferent, 317 but also because in the setting of peripheral neuropathy, if changes in conduction 318 velocity are observed, they have usually been reported to be a decrease in 319 conduction velocity. While in the setting of hypersensitivity states, one might 320 expect to observe an increase in conduction velocity, as a reflection of a change in 321 ionic conductance in the axon (Hodgkin, 1975 , Waxman et al., 1999 , in the 322 setting of inflammatory pain, conduction velocity has generally been unchanged 
